27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
These data demonstrate that donepezil is an effective and well-tolerated treatment for VaD and show it may have an important place in the management of this condition. 5 key findings →
Participants: 603 Evidence: high
Full summary, score breakdown and related studies → Original source
In a 24-week, randomized, double-blind, placebo-controlled, multicenter study of rivastigmine, 487 patients with dementia associated with Parkinson disease underwent assessment of attention on the Cognitive Drug Research computerized cognitive assessment system before dosing and 16 and 24 weeks later. 2 key findings →
Participants: 487 Evidence: high
Full summary, score breakdown and related studies → Original source
No significant difference was seen in cognitive and functional decline between early and delayed treatment groups. 4 key findings →
Design: clinical trial Participants: 85 Evidence: high
Full summary, score breakdown and related studies → Original source
SC gantenerumab at doses of up to 1,200 mg Q4W were well tolerated in participants with mild AD dementia. 2 key findings →
Design: open-label trial Participants: 225 Evidence: low
Full summary, score breakdown and related studies → Original source
Donepezil has significant efficacy in the treatment of neuropsychiatric symptoms in patients with mild to moderate AD. 4 key findings →
Design: open-label trial Participants: 134 Evidence: high
Full summary, score breakdown and related studies → Original source
Probiotics have been proposed to ameliorate cognitive impairment and depressive disorder via the gut-brain axis in patients and experimental animal models. 5 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
A low-dose regimen of prednisone is not useful in the treatment of AD. 3 key findings →
Participants: 138 Evidence: high
Full summary, score breakdown and related studies → Original source
Promotion of person centred care and good practice in the management of patients with dementia with behavioural symptoms provides an effective alternative to neuroleptics. 2 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
The cohorts had low pre-test probability (%Aβ positivity = 14.9-24.7) and were predominantly cognitively normal (> 73%). 5 key findings →
Design: cohort study Participants: 441 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Multivariable models (p-tau+GFAP+NfL) had the best performance to detect Aβ+ in NormCog (ROCAUC = 0.87) and ImpCog (ROCAUC = 0.87). 5 key findings →
Design: longitudinal study Participants: 132 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Plasma NfL and GFAP were associated with vascular brain damage and differed across states (VCI > vascular CU > non-vascular CI > non-vascular CU). 5 key findings →
Design: longitudinal study Participants: 1,810 Evidence: moderate
Full summary, score breakdown and related studies → Original source
A total of 17 articles were identified. Plasma Aβ42/40 ratio was inversely correlated with aPET positivity r = -0.48 (95% confidence interval (CI): -0.65--0.31). 5 key findings →
Design: systematic review Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source
The use of ecologically oriented approaches with virtual reality (VR) depicting instrumental activities of daily living (IADL) is a promising approach for interventions on acquired brain injuries. 2 key findings →
Design: randomized controlled trial Participants: 17 Evidence: high
Full summary, score breakdown and related studies → Original source
Participants in the experimental group had better overall subjective memory, subjective retrospective memory and global quality of life, with fewer depressive symptoms than those in the control group 3 months following the program. 3 key findings →
Design: randomized controlled trial Participants: 15 Evidence: high
Full summary, score breakdown and related studies → Original source
Over six months, the intervention group showed a stable global cognitive function score (Mini Mental Status Examination), whereas the control group showed a cognitive decline (ANCOVA-interaction: F1, 14 = 5.083, p = .041; controlled for disease duration and education). 5 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source
Our sample had a mean age of 66.8 (SD = 5.3) years, a mean HAM-D score of 19.4 (SD = 7.5), and a mean PHQ-9 score of 18.0 (SD = 6.3). 5 key findings →
Design: randomized controlled trial Participants: 28 Evidence: high
Full summary, score breakdown and related studies → Original source
Thinning of retinal layers, measured using optical coherence tomography (OCT), is associated with some neurodegenerative disorders such as established Alzheimer's disease and multiple sclerosis. 5 key findings →
Design: systematic review Participants: 622 Evidence: high
Full summary, score breakdown and related studies → Original source
The overall number of participants enrolled was 192, with a mean (standard deviation) amyloid PET load at baseline of 101.80 (29.80) centiloids. 5 key findings →
Design: clinical trial Participants: 149 Evidence: low
Full summary, score breakdown and related studies → Original source
Each matched cohort included 23,386 (semaglutide vs sitagliptin), 22,584 (vs empagliflozin), and 19,206 (vs glipizide) patients. 5 key findings →
Design: cohort study Participants: 23,386 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Emerging evidence suggests that treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) could be an interesting treatment strategy to reduce neurological complications such as stroke, cognitive impairment, and peripheral neuropathy. 3 key findings →
Design: systematic review Participants: 19 Evidence: high
Full summary, score breakdown and related studies → Original source
The sample was mostly female (65%), White (76%), and 74 years old on average. 5 key findings →
Design: retrospective cohort Participants: 342,608 Evidence: moderate
Full summary, score breakdown and related studies → Original source
AD patients aged 50-85 years were randomized to open-label treatment with oral rivastigmine, donepezil or galantamine for 13 weeks. 5 key findings →
Design: open-label trial Participants: 63 Evidence: high
Full summary, score breakdown and related studies → Original source
A total of seven studies were included. The forest plot results showed that taking lithium therapy reduced the risk of AD (RR 0.59, 95% confidence interval [CI]: 0.44-0.78) and is also protective in reducing the risk of dementia (RR 0.66, 95% CI: 0.56-0.77). 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source
A growing number of investigations are exploring the utility of intranasal insulin as a means of mitigating cognitive decline. 2 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source
Patients treated with galantamine 24 mg/day had a significantly better outcome than placebo on ADAS-cog; the treatment difference was 3 points on the intention-to-treat (ITT) analysis ( p = 0.01) and 4.2 points on per protocol analysis ( p = 0.001). 4 key findings →
Participants: 285 Evidence: high
Full summary, score breakdown and related studies → Original source
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →